AIM ImmunoTech (NYSE:AIM) Price Target Cut to $1.00 by Analysts at Maxim Group

AIM ImmunoTech (NYSE:AIM) had its price target dropped by equities researchers at Maxim Group from $2.00 to $1.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Maxim Group’s price target would indicate a potential upside of 271.75% from the company’s previous close.

Separately, Ascendiant Capital Markets reduced their price target on AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd.

AIM ImmunoTech Stock Up 1.5 %

AIM stock traded up $0.00 during mid-day trading on Tuesday, reaching $0.27. The company had a trading volume of 321,909 shares, compared to its average volume of 254,697. AIM ImmunoTech has a 52 week low of $0.21 and a 52 week high of $0.62. The company has a market capitalization of $13.85 million, a price-to-earnings ratio of -0.42 and a beta of -0.39. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.17 and a quick ratio of 1.17. The stock has a 50 day simple moving average of $0.30 and a two-hundred day simple moving average of $0.36.

AIM ImmunoTech (NYSE:AIM) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.03) earnings per share for the quarter. AIM ImmunoTech had a negative return on equity of 269.04% and a negative net margin of 13,952.74%. The business had revenue of $0.05 million for the quarter. As a group, equities analysts predict that AIM ImmunoTech will post -0.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC acquired a new position in shares of AIM ImmunoTech Inc. (NYSE:AIM) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned about 7.92% of AIM ImmunoTech as of its most recent SEC filing. 12.02% of the stock is currently owned by hedge funds and other institutional investors.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).